Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Avidity Biosciences (NASDAQ: RNA) has successfully closed its upsized public offering of 17,250,000 shares of common stock at $40.00 per share, including the full exercise of the underwriters' option for additional shares. The offering generated gross proceeds of $690.0 million.
The company plans to use the proceeds to advance its three late-stage clinical programs, build commercial inventory for multiple potential launches, expand commercial infrastructure, and progress research and development of its AOC™ (Antibody Oligonucleotide Conjugates) platform. The offering was managed by Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities as joint bookrunners.
Avidity Biosciences (NASDAQ: RNA) has announced the pricing of its upsized public offering of 15,000,000 shares of common stock at $40.00 per share. The offering is expected to generate gross proceeds of $600.0 million before deducting underwriting discounts and commissions.
The company has granted underwriters a 30-day option to purchase up to an additional 2,250,000 shares. The proceeds will be used to advance three late-stage clinical programs, build commercial inventory, expand infrastructure, progress AOC platform research, and for working capital. The offering is expected to close around September 15, 2025.
Avidity Biosciences (NASDAQ: RNA) has announced plans for a $500 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to $75 million of shares. The company, which specializes in Antibody Oligonucleotide Conjugates (AOCs™), will use the proceeds to advance three late-stage clinical programs, build commercial inventory, expand infrastructure, and support platform development.
The offering will be managed by joint bookrunners including Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities. The securities will be offered through a shelf registration statement that is already effective with the SEC.
Avidity Biosciences (NASDAQ: RNA) reported groundbreaking results from its EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 trials for del-zota, a treatment for Duchenne Muscular Dystrophy (DMD44). The drug demonstrated unprecedented improvement in multiple functional measures after one year of treatment.
Key achievements include a 25% increase in normal dystrophin production, with total dystrophin reaching up to 58% of normal levels. Creatine kinase levels showed sustained reduction of >80% to near-normal levels. The trials revealed significant improvements in functional measures including Time to Rise from Floor, 4-Stair Climb, Performance of Upper Limb, and 10-Meter Walk/Run Test, contrasting with natural disease progression.
The company plans to submit a Biologics License Application (BLA) for accelerated approval by the end of 2025, marking their first of three planned BLA submissions over 12 months.
Avidity Biosciences (NASDAQ: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three upcoming investor conferences in September 2025.
The management team will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley Global Healthcare Conference on September 8. Live webcasts and replays will be available on the company's investor relations website.
Avidity Biosciences (NASDAQ: RNA) reported significant progress in Q2 2025 across its key drug development programs. The company is preparing for three potential BLA submissions within a 12-month period, with its first commercial launch possible in 2026. Key highlights include FDA alignment on del-brax pathways for FSHD, positive Phase 1/2 FORTITUDE™ trial data, and planned del-zota BLA submission for DMD44 by year-end 2025.
Financially, Avidity maintains a strong position with $1.2 billion in cash and equivalents as of June 30, 2025, plus additional $185.5 million from ATM offering. Q2 2025 saw collaboration revenues of $3.8 million, while R&D expenses increased to $138.1 million and G&A expenses rose to $36.9 million. The company's cash runway extends to mid-2027, supporting global commercial launch preparations.
Avidity Biosciences (NASDAQ:RNA) has completed enrollment for HARBOR™, the first global Phase 3 trial of delpacibart etedesiran (del-desiran) for treating myotonic dystrophy type 1 (DM1). The company expects topline data in Q2 2026 and plans to submit marketing applications in the U.S., EU, and Japan starting in H2 2026.
Del-desiran, designed to address DM1's underlying genetic cause, has received multiple regulatory designations including Breakthrough Therapy, Orphan Drug, and Fast Track from the FDA. The HARBOR trial involves approximately 150 patients across 40 global sites, evaluating the drug's efficacy through various endpoints including video hand opening time (vHOT) and muscle strength measurements.
Avidity Biosciences (NASDAQ: RNA) has received FDA Breakthrough Therapy designation for delpacibart zotadirsen (del-zota) for treating Duchenne muscular dystrophy (DMD) in patients with mutations amenable to exon 44 skipping. The company is on track for BLA submission by end of 2025.
The Phase 1/2 EXPLORE44 trial demonstrated significant results, including statistically significant increases in exon skipping, substantial increase in dystrophin production, and significant reduction in creatine kinase levels to near normal. The company plans to present topline and functional data from the Phase 2 EXPLORE44-OLE trial in Q4 2025.
Del-zota has also received Orphan designation from FDA and EMA, plus Rare Pediatric Disease and Fast Track designations from FDA for DMD44 treatment.